"Hims & Hers Health (NYSE: HIMS) reports fiscal third-quarter earnings after the close. The telehealth innovator has become one of 2025's most closely watched growth stories as it continues scaling its precision-care platform across weight loss, sexual health, dermatology, and mental wellness. The stock has climbed sharply this year on expectations that its next wave of growth-hormonal health, lab testing, and AI-driven personalization-will widen its addressable market well beyond virtual prescriptions."
"Yet with the company now operating at scale, investors will be watching whether profitability can keep pace with the surge in subscribers and new initiatives. Wall Street anticipates Q3 FY2025 earnings of $0.10 per share on revenue of $579.85 million, reflecting about 44% year-over-year growth. Analysts see Q4 EPS rising to $0.13 as Hims benefits from higher daily-use adoption and international expansion."
Hims & Hers Health reports fiscal third-quarter earnings and continues scaling a precision-care telehealth platform across weight loss, sexual health, dermatology, and mental wellness. The stock gained on expectations that hormonal health, lab testing, and AI-driven personalization will expand the addressable market beyond virtual prescriptions. Investors will monitor whether profitability can keep pace with rising subscribers and new initiatives as the company operates at scale. Wall Street forecasts Q3 EPS of $0.10 on $579.85 million revenue, about 44% year-over-year growth, with analysts expecting Q4 EPS of $0.13 and full-year revenue of $2.35 billion.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]